1. Home
  2. GNL vs CAPR Comparison

GNL vs CAPR Comparison

Compare GNL & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Net Lease Inc.

GNL

Global Net Lease Inc.

HOLD

Current Price

$9.02

Market Cap

1.9B

Sector

Real Estate

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$4.32

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNL
CAPR
Founded
2011
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
2011
2011

Fundamental Metrics

Financial Performance
Metric
GNL
CAPR
Price
$9.02
$4.32
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$9.67
$44.63
AVG Volume (30 Days)
2.6M
5.6M
Earning Date
05-05-2026
05-12-2026
Dividend Yield
7.98%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$495,286,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.95
$3.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.45
$2.96
52 Week High
$10.04
$40.37

Technical Indicators

Market Signals
Indicator
GNL
CAPR
Relative Strength Index (RSI) 51.00 16.61
Support Level $8.84 $4.23
Resistance Level $9.66 $6.54
Average True Range (ATR) 0.20 0.80
MACD 0.04 0.07
Stochastic Oscillator 65.00 7.90

Price Performance

Historical Comparison
GNL
CAPR

About GNL Global Net Lease Inc.

Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operation, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution, Retail, and Office. The company derives maximum revenue from the Industrial and Distribution segment. The company geographically operates in the United States, the United Kingdom, Canada, and Europe.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: